Trial results

Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes

NCT07117240 on ClinicalTrials.gov · last registry update 2025-09-19

100 participants. Due to report 9 February 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: Glucose monitoring index and Time in range. Sponsors move these dates routinely; any movement since this site started watching is listed below. lixisenatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

ENROLLING_BY_INVITATION

Phase

P4

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

Medical University of Warsaw

Sponsor type

Other

Enrollment

100

Started

2025-07-10

Primary completion

2028-02-09 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Glucose monitoring index and Time in range

Conditions studied

Steroid-Induced Diabetes · Steroid-Induced Hyperglycemia · Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.